Log In
Print this Print this

Lucatumumab (HCD122) (formerly CHIR-12.12)

  Manage Alerts
Collapse Summary General Information
Company Xoma Corp.
DescriptionHuman mAb against CD40
Molecular Target CD40
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I/II
Standard IndicationLymphoma
Indication DetailsTreat lymphoma
Regulatory Designation
Partner Novartis AG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today